Wednesday, February 26, 2025 5:26:58 PM
rosemountbomber
Re: JRoon71 post# 433406
Wednesday, February 26, 2025 11:34:23 AM
They are 100% the same as the old management. The only logical explanation is denner miscalculated big time on the revenues in europe and row is now facing declining revenue. There really is no other explanation or I am not sure whey they would have ever taken over this company given how it has gone, given the massive headache it appears to be. I get its only 4% of their holding so maybe they honestly don't really care that much. They just be hoping to get out at some point to salvage their reputation at a small profit. But its same to say the days of hoping for 25 a share are long gone. Hoping for 4 a share now is the new norm.
Post#
433407
of 433415
JRoon, for a tiny minute long ago I used to accept the argument that they couldn't give away their ideas, tactics, whatever, for the sake of competitive advantage. Most other companies apparently don't seem to have that problem even if they are in very competitive industries and markets. To be fair, I think we all know the company is between a rock and a hard place with little they can do so I understand, BUT, BUT, BUT to me it is so surprising (the lack of communication, etc) because that is what they used against the previous management team to oust them. You would think that if anyone would realize this the most, it would be this group and it should be foremost in their minds to not mimic prior admins in this regard. So for that reason it is very surprising to me. Up till now, this management is no different (wrt actions and results) than the prior team other than the fact that they have put their own money on the line. That keeps me here.
Re: JRoon71 post# 433406
Wednesday, February 26, 2025 11:34:23 AM
They are 100% the same as the old management. The only logical explanation is denner miscalculated big time on the revenues in europe and row is now facing declining revenue. There really is no other explanation or I am not sure whey they would have ever taken over this company given how it has gone, given the massive headache it appears to be. I get its only 4% of their holding so maybe they honestly don't really care that much. They just be hoping to get out at some point to salvage their reputation at a small profit. But its same to say the days of hoping for 25 a share are long gone. Hoping for 4 a share now is the new norm.
Post#
433407
of 433415
JRoon, for a tiny minute long ago I used to accept the argument that they couldn't give away their ideas, tactics, whatever, for the sake of competitive advantage. Most other companies apparently don't seem to have that problem even if they are in very competitive industries and markets. To be fair, I think we all know the company is between a rock and a hard place with little they can do so I understand, BUT, BUT, BUT to me it is so surprising (the lack of communication, etc) because that is what they used against the previous management team to oust them. You would think that if anyone would realize this the most, it would be this group and it should be foremost in their minds to not mimic prior admins in this regard. So for that reason it is very surprising to me. Up till now, this management is no different (wrt actions and results) than the prior team other than the fact that they have put their own money on the line. That keeps me here.
Recent AMRN News
- Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy • IH Market News • 04/29/2026 02:19:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 11:06:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:15 AM
- Amarin Reports 2026 First Quarter Financial Results • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
